Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies

Next Previous
Trial Profile

A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Patients With Advanced Solid Tumors and Hematological Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Tizaterkib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms ERASER
  • Sponsors Antengene Corporation

Most Recent Events

  • 23 Jul 2024 Status changed from recruiting to discontinued. (The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.)
  • 04 Jun 2024 Results (n=21)from dose-escalation part, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 May 2024 Results presented in an Antengene Corporation Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top